S&P 500   4,561.87 (+0.15%)
DOW   35,523.19 (+0.30%)
QQQ   391.01 (+0.21%)
AAPL   189.43 (-0.51%)
MSFT   379.48 (-0.84%)
META   333.25 (-1.69%)
GOOGL   135.48 (-1.25%)
AMZN   146.99 (-0.03%)
TSLA   247.42 (+0.28%)
NVDA   482.15 (+0.82%)
NIO   7.22 (+0.14%)
BABA   74.97 (-2.31%)
AMD   124.51 (+2.05%)
T   16.31 (+0.80%)
F   10.66 (+2.80%)
MU   76.75 (+0.83%)
CGC   0.57 (+4.96%)
GE   119.06 (+0.18%)
DIS   92.99 (+0.53%)
AMC   7.26 (+8.36%)
PFE   30.08 (+1.31%)
PYPL   58.37 (-0.17%)
XOM   103.57 (-0.32%)
S&P 500   4,561.87 (+0.15%)
DOW   35,523.19 (+0.30%)
QQQ   391.01 (+0.21%)
AAPL   189.43 (-0.51%)
MSFT   379.48 (-0.84%)
META   333.25 (-1.69%)
GOOGL   135.48 (-1.25%)
AMZN   146.99 (-0.03%)
TSLA   247.42 (+0.28%)
NVDA   482.15 (+0.82%)
NIO   7.22 (+0.14%)
BABA   74.97 (-2.31%)
AMD   124.51 (+2.05%)
T   16.31 (+0.80%)
F   10.66 (+2.80%)
MU   76.75 (+0.83%)
CGC   0.57 (+4.96%)
GE   119.06 (+0.18%)
DIS   92.99 (+0.53%)
AMC   7.26 (+8.36%)
PFE   30.08 (+1.31%)
PYPL   58.37 (-0.17%)
XOM   103.57 (-0.32%)
S&P 500   4,561.87 (+0.15%)
DOW   35,523.19 (+0.30%)
QQQ   391.01 (+0.21%)
AAPL   189.43 (-0.51%)
MSFT   379.48 (-0.84%)
META   333.25 (-1.69%)
GOOGL   135.48 (-1.25%)
AMZN   146.99 (-0.03%)
TSLA   247.42 (+0.28%)
NVDA   482.15 (+0.82%)
NIO   7.22 (+0.14%)
BABA   74.97 (-2.31%)
AMD   124.51 (+2.05%)
T   16.31 (+0.80%)
F   10.66 (+2.80%)
MU   76.75 (+0.83%)
CGC   0.57 (+4.96%)
GE   119.06 (+0.18%)
DIS   92.99 (+0.53%)
AMC   7.26 (+8.36%)
PFE   30.08 (+1.31%)
PYPL   58.37 (-0.17%)
XOM   103.57 (-0.32%)
S&P 500   4,561.87 (+0.15%)
DOW   35,523.19 (+0.30%)
QQQ   391.01 (+0.21%)
AAPL   189.43 (-0.51%)
MSFT   379.48 (-0.84%)
META   333.25 (-1.69%)
GOOGL   135.48 (-1.25%)
AMZN   146.99 (-0.03%)
TSLA   247.42 (+0.28%)
NVDA   482.15 (+0.82%)
NIO   7.22 (+0.14%)
BABA   74.97 (-2.31%)
AMD   124.51 (+2.05%)
T   16.31 (+0.80%)
F   10.66 (+2.80%)
MU   76.75 (+0.83%)
CGC   0.57 (+4.96%)
GE   119.06 (+0.18%)
DIS   92.99 (+0.53%)
AMC   7.26 (+8.36%)
PFE   30.08 (+1.31%)
PYPL   58.37 (-0.17%)
XOM   103.57 (-0.32%)

Burning Rock Biotech Stock Price, News & Analysis (NASDAQ:BNR)

$0.89
+0.00 (+0.41%)
(As of 02:05 PM ET)
Compare
Today's Range
$0.87
$0.91
50-Day Range
$0.88
$1.13
52-Week Range
$0.87
$3.80
Volume
29,623 shs
Average Volume
78,151 shs
Market Capitalization
$91.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Burning Rock Biotech MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of Burning Rock Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.57) to ($0.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Business Services Sector

243rd out of 308 stocks

Medical Laboratories Industry

18th out of 23 stocks


BNR stock logo

About Burning Rock Biotech Stock (NASDAQ:BNR)

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

BNR Stock Price History

BNR Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Q2 2023 Burning Rock Biotech Ltd Earnings Call
Burning Rock Biotech Q2 Loss Narrows
Q1 2023 Burning Rock Biotech Ltd Earnings Call
Burning Rock Publishes 2022 Annual Report on Form 20-F
See More Headlines
Receive BNR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/31/2023
Today
11/29/2023
Next Earnings (Confirmed)
11/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:BNR
Fax
N/A
Employees
1,138
Year Founded
N/A

Profitability

Net Income
$-140,820,000.00
Net Margins
-130.84%
Pretax Margin
-126.22%

Debt

Sales & Book Value

Annual Sales
$81.66 million
Book Value
$1.64 per share

Miscellaneous

Free Float
71,542,000
Market Cap
$91.04 million
Optionable
Not Optionable
Beta
0.25
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














BNR Stock Analysis - Frequently Asked Questions

How have BNR shares performed in 2023?

Burning Rock Biotech's stock was trading at $2.25 at the beginning of the year. Since then, BNR shares have decreased by 60.0% and is now trading at $0.90.
View the best growth stocks for 2023 here
.

Are investors shorting Burning Rock Biotech?

Burning Rock Biotech saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 476,000 shares, a drop of 7.2% from the October 31st total of 512,700 shares. Based on an average daily trading volume, of 54,200 shares, the days-to-cover ratio is presently 8.8 days. Approximately 0.6% of the company's shares are short sold.
View Burning Rock Biotech's Short Interest
.

When is Burning Rock Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 30th 2023.
View our BNR earnings forecast
.

How can I listen to Burning Rock Biotech's earnings call?

Burning Rock Biotech will be holding an earnings conference call on Thursday, November 30th at 7:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Burning Rock Biotech's earnings last quarter?

Burning Rock Biotech Limited (NASDAQ:BNR) announced its quarterly earnings data on Thursday, August, 31st. The company reported ($0.18) earnings per share (EPS) for the quarter. The business had revenue of $20.17 million for the quarter. Burning Rock Biotech had a negative net margin of 130.84% and a negative trailing twelve-month return on equity of 68.51%.

What other stocks do shareholders of Burning Rock Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA), Teck Resources (TECK), Herman Miller (MLHR) and Immunic (IMUX).

When did Burning Rock Biotech IPO?

(BNR) raised $196 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 13,500,000 shares at a price of $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

Who are Burning Rock Biotech's major shareholders?

Burning Rock Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (3.97%), Barclays PLC (0.25%) and Lansdowne Partners UK LLP (0.12%).

How do I buy shares of Burning Rock Biotech?

Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BNR) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -